Skip to main content
. 2018 Jul 25;27(5):131–139. doi: 10.1007/s40629-018-0059-x

Fig. 1.

Fig. 1

Percentage of patients reporting treatment-related adverse events related to study drug: a in the different treatment groups: placebo, HDM-DBPC, and HDM-All. b Distribution according to local, systemic and serious adverse event (AE). (DBPC Phase: placebo n = 221, HDM DBPC n = 214; HDM-All n = 279). HDM-DBPC high-dose HDM allergoid AIT double-blind placebo controlled, HDM-RCT(UC) high-dose HDM allergoid AIT usual care controlled, HDM-ALL HDM-DBPC plus HDM-RCT(UC), AE adverse event